Interview with Sarabjit Kour Nangra, VP Research - IT, Angel Broking Faraan Tarique | Mumbai January 9, 2015 Last Updated at 16:00 IST Analysts are quite impressed by third-quarter results from Infosys as it turned out to be better than what they had ... Business Standard, 2 months ago
Infosys PAT higher than our expectations: Sarabjit Kour Nangra, Angel Broking - Economic Times, 2 months ago
1 images for "sarabjit kour nangra"
MUMBAI: Following the successful closure of the $3.2 billion merger with troubled drug maker Ranbaxy, Dilip Shanghvi-led Sun Pharma said on Wednesday that the company is initiating the integration of the business, which will make the combined entity ...Times of India, 1 day ago Ranbaxy suffers fresh jolt Calcutta Telegraph, 1 month ago Ranbaxy loses generic exclusivity over $6 billion Nexium market DNA India, 1 month ago Ranbaxy loses US generic exclusivity over $6 bn Nexium [DNA : Daily News & Analysis (India)] Pharmacy Choice, 1 month ago
Shares of Sun Pharma rose as much as 2.4% in intra-day trade on Wednesday, while those of Ranbaxy jumped 2.1%. Photo: Hemant Mishra/Mint Mumbai: Sun Pharmaceutical Industries Ltd, India's most valuable drug maker, has completed the $3.2 billion ...Livemint.com, 1 day ago Ranbaxy-Sun Pharma merger to create world's fifth-largest generic drug firm Business Today India, 1 day ago
The USFDA has imposed import alerts on Silvassa and Indore (formulation facilities for US) for IPCA. However, Hydroxychloroquine Sulfate and Propanolol Hydrochloride, which accounted for around 45% of its total US sales in FY2014, are exempted from ...MyIris, 1 day ago Should investors buy Ipca Labs after sharp fall? Economic Times, 2 days ago IPCA Labs tanks 9%, gets USFDA import alert for Ratlam unit Moneycontrol.com, 2 months ago IPCA shares down on USFDA import alert Hindu Business Line, 2 months ago
The 30-share Sensex ended 50 points lower at 28,112 and the 50-share Nifty declined 12 points to close at 8,531. Markets ended lower for the sixth straight session, amid volatile trades, as traders turned cautious and booked profits ahead of the March F&O expiry tomorrow. A sharp decline among the infrastructure, metals & mining and oil & gas stocks was evident on the bourses after the Standard & Poor's (S&P) Ratings Services suggested that Indian companies in ...Rediff.com, 1 day ago
Markets ended lower amid choppy trades as investors turned cautious and resorted to profit-booking ahead of the March F&O expiry which is due tomorrow. A sharp decline among the infrastructure, metals & mining and oil & gas stocks was evident ...Business Standard India, 2 days ago Sensex ends 118 points lower amid choppy trades Business Standard India, 2 days ago
Markets are trading flat with a negative bias in the late noon trades as investors turn cautious and resorted to profit-booking ahead of the March F&O expiry which is due tomorrow. selling pressure in capital goods, metal, real estate and power ...Smart Investor, 2 days ago
Shares of Lupin touched a record high of Rs 1,958 on Thursday, up 4.5 percent intraday. The US subsidiary received approval from US Food and Drug Administration (USFDA) for anti-inflammatory drug Celecoxib (Celebrex). The company has been selling ...Moneycontrol.com, 1 week ago Lupin Stock Gains on Pain Killer Drug Approval NDTV Profit, 1 week ago
The fourth quarter of the financial year is expected to be ‘soft’ for the IT industry with muted revenue growth. Cross-currency fluctuations have played a major part in the projections and companies — including TCS, Wipro and Mindtree — are expecting ...The Financial Chronicle, 1 week ago
At a time when IT exporters have voiced growth concerns, Wipro has maintained its guidance and is bullish about its prospects for the upcoming financial year. However, Wipro believes that some sectors are witnessing pullback in terms of capex and ...Hindu Business Line, 1 week ago
on your WebpageAdd Widget >Get your members hooked!